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Introduction
Primary liver cancer is one of the most common malignancies worldwide, which is characterized by high morbidity, short disease course, high-grade malignancy and poor prognosis. In recent years, the morbidity of liver cancer cases has significantly increased (1) . On the other hand, it still lacks satisfactory treatments. Conventional treatments for liver cancer include surgical excision, interventional therapy, radiotherapy, chemotherapy, and so on. Although surgery is the preferred treatment option, it is still unsatisfactory for combination with high cirrhosis morbidity and poor liver reserve. Moreover, clinical observations have shown that tumor recurrence rates are very high in patients with primary liver cancer who receive medical or surgical treatments. Therefore, there is an urgent need for exploring new alternative treatment modalities for liver cancer.
A considerable amount of preclinical researches and clinical trials have provided striking evidences that gene therapy may play a key role in the biological treatment of liver cancer (2) (3) (4) (5) (6) . However, some problems still remain to be solved in the clinical application of this new promising therapeutic modality. Especially, what is the optimal transgenic vector system and how to evaluate therapeutic gene expression level and therapeutic efficacy with non-invasive and sensitive method in vivo.
Currently, the most widely used transgenic vectors are viral vectors such as adenoviruses, retroviruses, lentiviruses, and so on. Although these viral vectors have received great attentions as gene delivering vehicles for liver cancer gene therapy, but there are still some concerns when utilizing these vectors either in vitro or in vivo. For example, the narrow host range, random integration, small vehicle capacity (limited to 8 kb) and difficulty in achieving high viral titers restricts the popularization of retroviral vectors (7) . And adenoviral vectors do not integrate into the host genomic DNA that reduces the risk of insertion mutation, but results in transient gene expression on the other hand, and immune response against adenoviral proteins limits repeated administration in vivo, and intravenous delivery of high titers of adenoviral vectors may induce severe hepatic inflammation (8) . Another vectors, lentiviruses vectors combine some advantages of both adenoviral vectors and retroviral vectors (i.e. long-term expression of the transgene and ability to transduce into both dividing and non-dividing cells), however it can insert into target cell genome and induce endogenous genes expression changes leading to oncogenicity as well (9) .
Recently baculovirus vectors have also captured growing attentions for the use of delivering therapeutic genes for liver cancer therapy purpose. Baculovirus can't carry out replication or transcription in mammalian cells, and don't induce cellular toxicity. Furthermore, baculovirus vectors have a packaging capacity of more than 100 kb and don't randomly insert recombinant genes into the host cell chromosomes (randomly integration may lead to mutations) (10, 11) .
Radionuclide reporter gene imaging is a non-invasive, sensitive and repetitive method to quantitatively monitor the transduction efficacy of therapeutic genes and the location and duration of therapeutic genes expression. The sodium-iodide symporter (NIS) reporter gene can encode a transmembrane ion channel protein, NIS, which can effectively participate in the uptake of radiounclides such as 131 I (scintigraphic imaging), 123 I (single photon emission computed tomography, SPECT), 125 I (SPECT), 124 I (positron emission tomography, PET) 94m TcO 4 2 (PET) and 99m TcO 4 2 (SPECT), and is considered as an excellent reporter gene for the real-time monitoring of target genes transduction and expression in vivo (12) . Therefore, in this study, we investigated the feasibility of using baculovirus-mediated NIS reporter gene to quantitatively monitor gene therapy in liver cancer cells.
Materials and Methods

Plasmids, Cell Lines and Reagents
The FBS-free DMEM and Bac-GFP vector was added to triplicate wells at a MOI of 400. A control group without Bac-GFP incubation was included. After 4 h incubation, cells were washed twice with PBS and then fresh media was added. Cells were harvested after 1, 3, 5 and 7 d, stained with 0.4% Trypan Blue and viable cells were counted using a hemocytometer.
Iodide Uptake Assay
HepG2 cells were seeded into 24-well plates at 5 3 10 4 cells/ well. After 24 h, medium was replaced with 0.5 ml of FBS-free DMEM and Bac-NIS vector was added to triplicate wells at MOIs of 0, 100, 200 and 400. After 4 h incubation, medium was replaced with DMEM containing 10% FBS and cells were incubated for a further 24 h. Cells were then washed twice with PBS, then 500 μl PBS containing 0.1 μCi Na 125 I and 10 μmM NaI was added to each well, as described previously by Weiss et al. (14) . After 30 min incubation, medium was removed and cells were washed twice with ice-cold PBS, then 500 μl anhydrous ethanol was added to each well to lyse cells. After 20 min, ethanol was transferred into tubes and radionuclide incorporation was measured using a gamma-ray counter (Shanghai Rihuan Company, Shanghai, China). In dynamic uptake experiments, cells were assayed after 0, 5, 10, 15, 30, 60, 90 and 120 min incubation with Na 125 I/NaI solution.
NaClO 4 Inhibition Assays
HepG2 cells were prepared and transduced with Bac-NIS at a MOI of 200, as described above. After 24 h, medium was removed and cells were washed twice with PBS, then 500 μl PBS containing 0.1 μCi Na 125 I and 10 μM NaI was added to each well. Replicate wells containing 0, 30 and 300 μM NaClO 4 were included. After 30 min incubation, radionuclide incorporation was determined as described above.
Determining the Correlation of Fluorescent Intensities and 125 I Uptake Levels in HepG2 Cells after Co-vector Administration with Bac-NIS and Bac-GFP at Different MOIs
HepG2 cells were seeded into 24-well plates at 5 3 10 4 cells/ well. After 24 h, medium was changed to FBS-free DMEM before transduction. Bac-GFB and Bac-NIS were added at MOIs of 0, 25, 50, 100 and 200 (6 wells for each MOI), respectively. The total MOI account for both viruses was 0, 50, 100, 200 and 400. After 4 h incubation, cells were washed twice with 500 μl PBS and 500 μl DMEM containing 10% FBS was added to each well. After 24 h, three wells in each MOI group were used transduction to measure the Bac-GFP transduction efficiency and expression levels, and cells in the rest three wells was used to measure the 125 I uptake amount as described above.
Construction of Baculovirus Vectors Expressing NIS (Bac-NIS) and Green Fluorescent Protein (Bac-GFP)
We cloned the recombinant NIS gene into the pFBNIS baculovirus plasmid. Briefly, the pcDNA-NIS plasmid was used as a source of NIS cDNA, which was then subcloned into the pFB baculovirus vector and sequenced.
And then, we constructed baculoviruses expressing recombinant NIS (Bac-NIS) and green fluorescent protein (Bac-GFP) as previously described (13) . Briefly, recombinant baculovirus plasmids pFBGFPR and pFBNIS were used to transduce DH 10 competent bacteria. After selection and amplification of positive clones, Bacmid plasmids were purified and used to transfect Sf9 cells using a lipofection according to manufacturer's protocol (Invitrogen). Supernatants containing recombinant baculovirus were collected after 57 d. Virus titers were determined using plaque assays. For virus amplification, Sf9 cells were inoculated at a multiplicity of infection (MOI) of 0.1 and supernatant containing recombinant virus was harvested after 57 d by centrifugation at 8,500 g for 15 min at 4°C. Cell supernatant was clarified by centrifugation at 8,500 g for 30 min at 4°C, and passed the supernatant through a 0.45 μm filter. Recombinant baculovirus stocks were stored at 4°C in the dark, and plaque assays were used to determine the final titers.
Cell Culture
HepG2, A549, 8505C and SW1116 cells were cultured in DMEM medium containing 10% FBS, 1% penicillin-streptomycin at 37°C under 5% CO 2 in humidified incubator, and cells were subcultured when reached 80% confluency.
Baculovirus Transduction Efficiency and GFP Expression in Tumor Cells
HepG2, A549, SW1116 or 8505C cells were seeded into 24-well plates at 5 3 10 4 cells/well. After 24 h incubation, medium was replaced with 0.5 ml/well FBS-free DMEM and triplicate wells were transduced with Bac-GFP virus at a MOI of 0, 100, 200 or 400. Duplicate wells additionally contained 5 μM of sodium butyrate. After 4 h incubation, cells were washed twice with 500 μl phosphate buffer saline (PBS) and 500 μl DMEM containing 10% FBS was added to each well. After 24 h, GFP expression was examined using a fluorescence microscope. Flow cytometer was used to measure the proportion of HepG2 cells expressing green fluorescence and the mean fluorescence intensity. The blue light excitation wavelength was 488 nm and the detection wavelength was 520 nm.
Cell Viability Assay
HepG2 cells were seeded into 12-well plates at 1 3 10 5 cells/ well. After 24 h, medium was replaced with 0.5 ml/well of 
Statistical Analysis
All data were processed using SAS ver. 8.02 software (SAS Institute Inc., Cary, NC, USA), and all graphs were drawn using GraphPad Prism ver. 5.01 software (GraphPad Software Inc., La Jolla, CA, USA). All values were expressed as mean  standard deviation (SD). Continuous variables were compared by the paired Student's t-test. Differences between groups were compared by ANOVA using Dunnett's Multiple Comparison Test. P-values less than 0.05 (two-tailed) were considered to be significant.
Results
Sodium Butyrate Enhances Baculovirus Transduction Efficiency in HepG2 Cells
Using a GFP reporter gene, we found that HepG2 cells expressed obvious green fluorescence following incubation with recombinant Bac-GFP ( Figure 1A ) and the addition of sodium butyrate increased the GFP expression level, which showed higher fluorescence intensity ( Figure 1B ). Flow cytometry further quantitatively showed that the transduction efficiency of Bac-GFP in HepG2 cells increased with increasing MOI: at a MOI of 200, the transduction rate was 61% and at a MOI of 400 the transduction efficiency was 73%. Sodium butyrate significantly enhanced transduction efficiency: at a MOI of 200, 94% of the HepG2 cells became transduced and this increased to 97% at a MOI of 400 ( Figure 1C ). The fluorescence intensity of GFP expression also rose with increasing MOI, and was significantly enhanced by addition of sodium butyrate ( Figure 1D ).
Sodium Butyrate Enhances Baculovirus-mediated Ectopic Gene Expression Levels in a Range of Tumor Cells
The ability of baculovirus vectors to mediate gene expression in the non-liver cancer-derived cell lines, A549, 8505C and SW1116 cells, was also tested. Flow cytometry showed that there were differences in the rate of baculovirus-mediated transduction efficiency for different tumor cells. However, sodium butyrate could significantly increase transduction efficiency of each tumor cell line (Figure 2A ). HepG2 cells had a significantly higher transduction rate than other tumor cells in the absence of sodium butyrate. Although the transduction efficiency of A549 cells was the lowest in the absence of sodium butyrate, this cell line showed the greatest effect of sodium butyrate on improving the recombinant baculovirus transduction efficiency. The basal transduction efficiency of 8505C cells was also very low, but in contrast to A549 cells transduction efficiency was only slightly improved by sodium butyrate addition. There were also significant differences on mean fluorescence intensity of these transduced tumor cell lines. The basal expression intensity in HepG2 cells was significantly higher than that of the other three types of tumor cell lines. Although the improvement on mean fluorescence intensity due to the sodium butyrate was significant in all four tumor cell lines, it was much greater in HepG2 cells than in the other three tumor cell lines ( Figure 2B ).
Baculovirus Transduction does not Affect HepG2 Cell Viability
To investigate whether baculovirus transduction had any effects on cell viability, we compared cell number of HepG2 cells transduced with recombinant baculovirus at a MOI of 400 and mock-transduced cells up to 7 days post-transduction. We found that cell number curves were identical for transduced and mock-transduced cells up to 5 days post-transduction, and that there was a slight decrease in viability of transduced cells 7 days post-transduction, however this was not significant ( Figure 2C ). Thus, we indicated that baculovirus transduction was not cytotoxic to liver tumor cells.
NIS-mediated Iodide Uptake in HepG2 Cells is Dose-dependent
To investigate the ability of ectopic NIS to mediate radioiodide uptake in Bac-NIS-transduced HepG2 cells, we added Na 125 I to transduced cells and measured radioactivity incorporated into the cells after 30 minutes. We found that 125 I incorporation increased with increasing baculovirus MOI. Cells transduced at a MOI of 200 exhibited 16-fold higher radioiodide uptake than non-transduced cells ( Figure 3A ).
Dynamic Iodide Uptake in HepG2 Cells Expressing Ectopic NIS
A time course of 125 I uptake in Bac-NIS-transduced HepG2 cells showed a sharp increase in radioiodide incorporation up to 60 minutes followed by a gradual decline to approximately 50% of the maximal incorporation ( Figure 3B ). This data indicates that ectopic NIS can function on the cell membrane to effectively mediate iodide uptake. However, unlike the endogenous NIS in thyroid cells, baculovirusmediated ectopically expressed NIS could not effectively carry out iodide organification and storage, therefore the radioiodide incorporated by transduced HepG2 cells could not be effectively retained.
NaClO 4 Inhibits Iodide Uptake in HepG2 Cells
Sodium perchlorate (NaClO 4 ) is a proven NIS inhibitor. We therefore investigated whether NIS expressed ectopically in Bac-NIS-transduced HepG2 cells could also be inhibited by NaClO 4 . As expected, a concentration of 30 μM NaClO 4 effectively inhibited 125 I uptake in Bac-NIS-transduced HepG2 cells with a high inhibition rate of 72%, and the inhibition rate was not significantly increased by increasing the NaClO 4 concentration to 300 μM ( Figure 3C ). This data indicates that radioiodide uptake mediated by NIS protein in Bac-NIS-transduced HepG2 cells could be inhibited by the Na 1 /K 1 -ATP enzyme inhibitor, NaClO 4 , as its endogenous counterpart.
The GFP Fluorescence Intensity Correlates with NISmediated 125 I Uptake in HepG2 Cells after Co-vector Administration
After co-vector administration at total viral MOIs of 50, 100, 200 and 400, the correlation coefficient between the fluorescence intensities and radioactive counts was high (Pearson r 5 0.9191) ( Figure 3D ). This high correlation coefficient indicated that a significant correlation exists between the expression levels of GFP and NIS in the co-transduced liver cancer cells. These results demonstrated that the measurement of incorporated radioiodide mediated by NIS reporter gene might be used to indirectly reflect the expression level of GFP or other target therapeutic genes when used the baculovirus transgenic vector. 
Discussion and Conclusion
Primary liver cancer has one of the highest mortality rates. At present, the main treatments for liver cancer include surgery, chemoembolization, liver transplantation, and so on, but these treatments all have a poor prognosis. Therefore, searching more ideal treatments for advanced liver cancer is still an important issue that needs to be solved urgently. In recent years, the development of molecular biology technology has led to advances in liver cancer gene therapy strategies, such as gene directed enzyme/pro-drug therapy (15) , inhibition of oncogenes (16) , restoration of tumor-suppressor genes (17) , immunogenic therapy (4), and antisense gene therapy (18) .
However, the efficacy of gene therapy for liver cancer will depend not only on the selection of adequate therapeutic genes to achieve the desired goal, but also on efficient therapeutic gene transduction facilitated by the use of transgenic vectors, duration of transgene expression in the cancer cells, toxicity of the vectors and the activity of regulatory elements used to control transgene expression. Therefore, an optimal transgenic vector is likely to be critical in optimizing gene therapy.
Transgenic vectors currently include viral vectors and nonviral vectors. Non-viral vectors are safer, but transduction efficiency is very low. Therefore, viral vectors are still the most effective tools for gene transduction, and the most widely used vectors are retrovirus, lentivirus and adenovirus. Although their potential clinical application has been proven in many studies, these viral vectors have their respective shortcomings, particularly in terms of safety.
Retroviruses and lentivirus are common transgenic vectors, but both of they can randomly integrate into transcriptionally active regions of the genome, causing insertional mutagenesis, oncogene activation and cellular transformation (7, 19) . Adenovirus vectors have been widely used for gene therapy, and their probability of insertional mutagenesis is very low, but the human immune system is generally activated against adenoviruses (20).
In recent years, exogenous gene expression mediated by insect-derived baculovirus as gene transfer vector in mammalian cells has attracted more and more attention (21) . Compared with other viral vectors, baculovirus vectors have been proved they do not integrate into host cells genome to replicate and have no cytotoxicity to mammalian cells. Also after a certain time, viral genes will degrade, which reduces the possibility of side effects occurrence. In addition, baculovirus is a kind of insect virus in natural environment, and mammals have no potential antibody and specific T cell against it in vivo. Furthermore, mammals can effectively avoid vector neutralization (22) . Therefore, baculovirus vector has the extremely high biosafety. As baculovirus has no pathogenicity, it is feasible to carry out trials with baculovirus in biosafety level 1 laboratory. Moreover, preparation method of recombinant baculovirus is simple, and it can obtain high titers of recombinant virus (10, 23) .
In this study, we successfully constructed and prepared recombinant baculovirus expressing GFP gene (Bac-GFP) under the control of the cytomegalovirus (CMV) promoter. Bac-GFP transduction showed large differences on the transduction efficiency in different tumor cell lines, and the transduction efficiency of the hepatocellular carcinoma cell line, HepG2, was significantly higher than that of other tumor cell lines, even if in absence of sodium butyrate. Furthermore, there was no cytotoxicity detected in this study. These results therefore might provide a basis for baculovirus vector-mediated gene therapy for liver cancer.
We found that recombinant baculovirus transduction efficiency differed significantly between tumor cells from different tissues, which may be associated with differential expression of baculovirus receptor on the different tumor cells surface. However, it is also possible that other mechanisms are responsible. For example, it is currently thought that the baculovirus envelope protein, gp64, plays a key role in baculovirus entry into mammal cells (24) , for gp64 is critical for adsorption of virus particles and their escape from inclusion body. Moreover, cell surface clathrin-mediated endocytosis and macropinocytosis can allow viruses to enter cells (25, 26) , although the specific mechanism for baculovirus entry into mammal cells is still unclear so far.
Sodium butyrate is a histone deacetylase (HDAC) inhibitor that can significantly improve baculovirus transduction efficiency and CMV-regulated-gene expression, possibly associated with its histone deacetylase inhibitory function (27) . HDAC inhibitor can induce chromatin relaxation by inducing hyperacetylation of histidine proteins. However, high concentrations of HDAC inhibitors exhibits cytotoxicity and may also induce apoptosis, and even have an adverse effect on baculovirus transduction efficiency for different promoters and cell lines (28) . Therefore, it is problematic to use sodium butyrate to increase baculovirus transduction efficiency in tumor cells in animal models. This study demonstrated that baculovirus has a very high transduction efficiency in HepG2 cells even without sodium butyrate, suggesting that the baculovirus vector system is adequate for gene delivery in this tumor cell line.
However, the inability to monitor therapeutic gene expression in real time during the treatment creates substantial difficulties in experimental or clinical protocol design, in ongoing evaluation of therapeutic efficacy during treatment, and in alterations in treatment in response to individual variation. If therapeutic gene expression could be non-invasively, quantitatively and repetitively monitored in real time, it may provide serial measurements of the location, magnitude and duration of therapeutic gene expression. Therefore, it is usually necessary to develop and validate indirect imaging strategies by using a radionuclide reporter gene in combination with a therapeutic gene. This approach with radionuclide reporter gene systems achieves the goal of repeatedly, noninvasively and quantitatively monitoring therapeutic gene expression, and also overcomes the weaknesses of other modalities, such as magnetic resonance imaging using superparamagnetic iron oxide (SPIO) nanomagnetic particles, which cannot distinguish dead cells from live cells (29, 30) .
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There are several radionuclide reporter genes have been commonly used for imaging, such as the enzyme-based herpes simplex virus-thymidine kinase (HSV-tk) reporter gene, the receptor-based dopamine D2 receptor (hD2R) reporter gene, and the transporter-based sodium-iodide symporter (hNIS) reporter gene and norepinephrine transporter (hNET) reporter gene. Among these well-known reporter genes, the NIS reporter gene is considered as one of the most promising reporter genes (12) . Compared with other reporter genes, the advantages of exploiting the hNIS gene as a radionuclide reporter gene for monitoring the gene therapy include the following, as a human protein, the expressed product of NIS should theoretically be non-immunogenic; several radionuclide probes used in the NIS reporter gene imaging system already have been approved for clinical application and are available for SPECT or PET imaging, such as 131 I, 123 I, 124 I and 99m Tc-pertechnetate, etc., which can be easy to obtain without complicated chemical synthesis. These properties render the NIS reporter gene suitable for dynamically monitoring in real-time the expression level and duration of target genes (30, 31) .
Therefore, in this study, we also constructed and prepared recombinant baculovirus expressing NIS reporter gene (Bac-NIS) under the control of the CMV promoter as well, and tested the NIS-mediated radioiodide uptake in liver cancer cells in the absence of sodium butyrate in vitro. In our experiment, NIS expression induced functional radioiodide uptake in a perchlorate-sensitive manner, indicating that ectopically expressed NIS mediated by baculovirus has the same functional characteristics as its native counterpart in the thyroid cell membrane.
Since the expression level of most therapeutic genes cannot be quantified directly using imaging, there is a necessity to develop the approaches of coordinately expressing the target therapeutic gene and NIS reporter gene to perform indirect imaging. Currently, there are several approaches to combine reporter genes and target genes (32, 33) , such as gene/ protein fusion approach, bicistronic approach using internal ribosomal entry site (IRES), dual-promoter approach, bidirectional transcriptional approach and co-vector administration approach. Every approach has its own advantages and disadvantages. Although fusion proteins display the best correlation, fusion of two genes or proteins may lead to changes in protein spatial configuration and consequently influence their functional activities. In the bicistronic IRES approach, reporter genes and therapeutic genes are separated by IRES. Although IRES facilitates the translation of two proteins simultaneously, translation from the IRES can be cell-typespecific and the expression level of the gene located distal to the IRES is often attenuated, which can lead to a lower imaging sensitivity.
In the co-vector administration approach, a therapeutic gene and a reporter gene are cloned into two separated vectors and controlled by the same type of promoter. This approach may eliminate the need for making a new construction for each therapeutic gene, and has been validated through the expression of two reporter genes mediated by other vectors and showed good correlation (34) (35) (36) . Since the expression levels of both NIS and GFP reporter gene can be measured quantitatively, and once administered, baculoviruses carrying the these two reporter genes have a statistically equivalent chance to transduce every target cancer cell; therefore, they can be used to validate the correlation between the expression levels of these two genes via baculovirus cotransduction approach. In this study, we used Bac-GFP and Bac-NIS to co-transduce liver cancer cells with same MOIs, where GFP gene is considered as therapeutic gene and NIS gene as reporter gene. The results showed that the application of equivalent MOIs of separate vectors carrying these two genes yielded a good correlation for the mean fluorescence intensities and the uptakes of radioactive reporter probes, which demonstrate the feasibility of using the NIS reporter gene to indirectly monitor target therapeutic gene expression level and in situ distribution by measuring the radioactivity accumulation with nuclear imaging devices. Moreover, for the dual role of NIS gene in gene therapy applications as both a nuclear imaging reporter gene and a cancer therapeutic gene, the radionuclides accumulated into the target cancer cells mediated by NIS can also function as radiotherapy, which may enhance the cancer therapy efficacy for liver cancer (37, 38) .
In order to adapt our strategy for future applications in targeted baculovirus-mediated therapeutic gene and reporter gene transduction for hepatocellular carcinoma gene therapy and monitoring, we could use either the alpha fetoprotein (AFP) promoter and enhancer (39) or hepatocarcinoma-intestinepancreas (HIP) promoter (40) and non-hepatocellular carcinoma cells both in vitro and in vivo. They found that NIS gene was specifically expressed only in transduced hepatocellular carcinoma cells, and not in normal hepatocytes or non-hepatocellular carcinoma cells. In addition, the main obstacle of using baculovirusmediated intracorporeal gene therapy for tumor lies in serum complement inactivation (41) . The baculovirus-activated complement system can reduce transduction efficiency and even prevent gene expression (42) . However, some studies showed that human decay-accelerating factor (DAF) expression accompanied by increased complement-regulatory protein was resistant to complement inactivation (43) . However, the prevention of complement inactivation still requires further research.
Due to their large packing capacity, good biosafety properties and lack of cytotoxicity, baculovirus vectors have potential applications for liver cancer gene therapy. We have shown that baculovirus could efficiently transduce hepatocellular carcinoma cells in vitro, and that recombinant NIS induced significant radioiodide uptake in baculovirus-transduced hepatocellular carcinoma cells and the radioactivity of accumulated radioiodide correlates with GFP fluorescence intensity after co-vector administration with Bac-NIS and Bac-GFP. In summary, this study provides a promising approach and a good experimental basis for further studies of baculovirus-mediated therapeutic gene expression monitoring and evaluation in liver cancer cells.
